Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 5475

Next Previous
X
Search
Drug Profile

MK 5475

Alternative Names: MK-5475

Latest Information Update: 02 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Pulmonary arterial hypertension
  • Phase II Pulmonary hypertension

Most Recent Events

  • 02 Jul 2024 Merck Sharp & Dohme completes a phase II/III INSIGNIA-PAH trial in Pulmonary arterial hypertension in USA, Argentina, Australia, Canada, Colombia, France, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russia, Turkey, Sweden, Belgium, United Kingdom (Inhalation) (NCT04732221)
  • 25 Oct 2023 Merck initiates enrolment in a phase II trial for Pulmonary hypertension in Argentina, Australia, Colombia, Croatia, France, Germany, Isreal, Italy, Mexico, and the United Kingdom (NCT05612035)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Pulmonary-hypertension in Israel (Inhalation, Powder)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top